HighPoint Advisor Group’s Tenaya Therapeutics TNYA Stock Holding History

HighPoint Advisor Group’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.7K	Hold	21,300	–	–	﹤0.01%	642
2025 Q4	$15.2K	Sell	21,300 -30,200	-59%	-$41.1K	﹤0.01%	1067
2025 Q3	$83.4K	Hold	51,500	–	–	﹤0.01%	676
2025 Q2	$31.5K	Hold	51,500	–	–	﹤0.01%	674
2025 Q1	$24.9K	Sell	51,500 -25,110	-33%	-$24.8K	﹤0.01%	654
2024 Q4	$72.3K	Buy	76,610 +7,720	+11%	+$17.3K	﹤0.01%	658
2024 Q3	$134K	Hold	68,890	–	–	0.01%	641
2024 Q2	$256K	Sell	68,890 -1,500	-2%	-$6.2K	0.02%	522
2024 Q1	$301K	Hold	70,390	–	–	0.02%	469
2023 Q4	$342K	Buy	+70,390	New	+$152K	0.02%	435

Other funds holding TNYA

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BGM

Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighPoint Advisor Group's TNYA Position: Q1 2026 in Review

HighPoint Advisor Group held its Tenaya Therapeutics (TNYA) position steady in Q1 2026 at 21,300 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #642.

HighPoint Advisor Group first reported a position in TNYA in Q4 2023 and has held it in 10 quarters since. The position peaked at $342K in Q4 2023. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

HighPoint Advisor Group held 21,300 shares of Tenaya Therapeutics worth $14.7K as of Q1 2026.
HighPoint Advisor Group left its Tenaya Therapeutics share count unchanged in Q1 2026.
Tenaya Therapeutics made up ﹤0.01% of HighPoint Advisor Group's portfolio in Q1 2026, its #642 holding.
HighPoint Advisor Group first reported a position in Tenaya Therapeutics in Q4 2023 and has held it in 10 quarters since.
HighPoint Advisor Group's Tenaya Therapeutics position peaked at $342K in Q4 2023.
103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.